June 12, 2012—White House and pharmaceutical industry communications released by House Energy and Commerce Committee Republicans late last week shed light on the negotiations over closing the Part D “donut hole” and expanding the 340B drug discount program in the days leading up to final passage of the Affordable Care Act (ACA) in early 2010.
According to a Feb. 21, 2010 email exchange between two Pharmaceutical Research and Manufacturers (PhRMA) officials, Jeffrey Kindler, who was then Pfizer’s chief executive officer, called a senior White House staff member that day and “got promised [a] 340B fix and a good outcome on” the separate agreement under which the industry agreed to provide deep discounts to Medicare Part D beneficiaries in that program’s coverage gap.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)